Value

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Five things for pharma marketers to know: Wednesday, November 16, 2016

Five things for pharma marketers to know: Wednesday, November 16, 2016

By

The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing

Five things for pharma marketers to know: Tuesday, June 7, 2016

Five things for pharma marketers to know: Tuesday, June 7, 2016

By

Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

By

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

4 Ways to Create a Sustainable Pricing Model

4 Ways to Create a Sustainable Pricing Model

The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

OPINION

Newsletters